<DOC>
	<DOC>NCT01316601</DOC>
	<brief_summary>Test safety and efficacy and of a novel IL-13 AB in the treatment of perianal fistulas - Trial with medicinal product</brief_summary>
	<brief_title>A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Inclusion criteria: diagnosis of Crohn's disease &gt; 6 month with fistula at least 1 ineffective fistula treatment in the past Exclusion criteria: TNF a antibody treatment failed in the past planned surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>